EUVIMEDEUVIMED entdecken
Crossref

Hyperthermic intrathoracic chemotherapy (HITHOC): A tertiary oncological center experience

Dejan Stojiljković, Sanja Mitrović, Ana Cvetković, Vladimir Cvetić, Ana Aleksić, Tanja Stojiljković, Igor Spurnić

Medicinska istrazivanja · 2025

DOI: 10.5937/medi0-57959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicinska istrazivanja, 2025. Verfasst von Dejan Stojiljković und 6 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to present our experience with HITHOC in the field of multimodality treatment of heterogeneous, potentially resectable, chemotherapy-sensitive pleural malignancies-primary and metastatic-limited to the unilateral thoracic inlet.

Methods

The research included all patients who underwent a HITHOC procedure with CRS at the Institute for Oncology and Radiology of Serbia from January 2018 to December 2024. The indications for procedure were: resectable chemo-sensitive primary or residual/recurrent thoracic malignancies confined to one side of the thorax, and various metastatic diseases restricted to the unilateral thoracic inlet with achieved local disease control. HITHOC was performed with cisplatin (100 mg/m2 in 1000 ml of 5 % glucose, gradually heated to 42 °C) perfusion lasting 90 minutes.

Results

Eleven patients were included in the study, with a mean age of 48.27 ± 18.37 years. The most common tumor pathology was thymoma, followed by malignant pleural tumors. Other tumor pathologies included ovarian cancer, Ewing's sarcoma, alveolar rhabdomyosarcoma, and lung cancer. Average follow-up was 41,73 (median: 35; range: 2-72) months. The overall survival rate was 64%.

Conclusion

HITHOC procedure can be regarded as a safe, feasible, and effective approach for well-selected patients. It could be beneficial not only for its current indications, but also for chemosensitive pleural malignancies, both primary and metastatic, limited to the unilateral thoracic inlet.

Zitieren

APA

Stojiljković, D., Mitrović, S., Cvetković, A., Cvetić, V., Aleksić, A., Stojiljković, T., & Spurnić, I. (2025). Hyperthermic intrathoracic chemotherapy (HITHOC): A tertiary oncological center experience. Medicinska istrazivanja. https://doi.org/10.5937/medi0-57959

Vancouver

Stojiljković D, Mitrović S, Cvetković A, Cvetić V, Aleksić A, Stojiljković T, et al. Hyperthermic intrathoracic chemotherapy (HITHOC): A tertiary oncological center experience. Medicinska istrazivanja. 2025. doi:10.5937/medi0-57959

BibTeX
@article{Stojiljkovi2025,
  author = {Stojiljković, Dejan and Mitrović, Sanja and Cvetković, Ana and Cvetić, Vladimir and Aleksić, Ana and Stojiljković, Tanja and Spurnić, Igor},
  title = {Hyperthermic intrathoracic chemotherapy (HITHOC): A tertiary oncological center experience},
  journal = {Medicinska istrazivanja},
  year = {2025},
  doi = {10.5937/medi0-57959}
}
Kostenlos starten →